A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice
A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice
复制标题
DOI：
10.1046/j.1365-2125.2002.01666.x
复制
发表时间：
2002-11-01
影响因子：
3.4
通讯作者：
Tett, S
中科院分区：
文献类型：
--
作者：
Cutts, C;LaCaze, A;Tett, S
新的环氧合酶-2（考克斯-2）选择性抑制剂塞来昔布（Celebrex（R））和罗非昔布（Vioxx（R））自上市以来已被广泛使用。目前在澳大利亚的处方模式的文献中没有出现任何评论。本文介绍了一种自我审计的选择性考克斯-2抑制剂治疗的临床使用农村全科医生（GPs）在Australia.Methods的结构化审计表的开发和分发给感兴趣的全科医生。该表格是自我管理，并集中在有关考克斯-2抑制剂和接受他们的患者的类型，例如适应症，患者人口统计学，危险因素和药物相互作用的问题。结果共招募了627例患者（569塞来昔布和58罗非昔布）。开了一系列剂量的处方。骨关节炎是最常见的适应症（68.1%）。已知的非选择性非甾体抗炎药的危险因素在65.1%的患者中被确定，最常见的是高龄，高血压和既往消化性溃疡疾病。潜在的药物相互作用很常见。各种原因开始治疗被确定，这些包括提高疗效，安全性和失败的其他treatment.Conclusions这些结果表明，考克斯-2抑制剂被规定为多个危险因素，可能会使患者在药物不良反应的风险增加考克斯-2抑制剂的患者。安全性和有效性改善的感觉很常见，值得关注。研究的局限性包括依赖自我报告。
Aims The new cyclooxygenase-2 (COX-2) selective inhibitors, celecoxib (Celebrex(R)) and rofecoxib (Vioxx(R)), have been widely prescribed since their launch. No reviews currently appear in the literature of prescribing patterns in Australia. This paper describes a self-audit of the clinical use of selective COX-2 inhibitor therapy undertaken with rural general practitioners (GPs) in Australia.Methods A structured audit form was developed and distributed to interested GPs. The form was self-administered and focused on issues about COX-2 inhibitors and the types of patients who were receiving them, e.g. indications, patient demographics, risk factors and drug interactions.Results A total of 627 patients were recruited (569 celecoxib and 58 rofecoxib). A range of doses was prescribed. Osteoarthritis was the most common indication (68.1%). Risk factors known for the nonselective nonsteroidal anti-inflammatory drugs were identified in 65.1% of patients, with the most common being advanced age, hypertension and previous peptic ulcer disease. Potential drug interactions were common. A variety of reasons for initiation of therapy was identified; these included perceived increased efficacy, safety and failure of other treatment.Conclusions These results show that COX-2 inhibitors are being prescribed for patients with multiple risk factors that may place the patient at increased risk of adverse drug reactions to a COX-2 inhibitor. The perception of improved safety and efficacy was common and is of concern. Limitations of the study include the reliance on self-reporting.